| IPO Company Profile |
| SEC Filings | Peer IPO Companies |
| Dyax Corp. |
| One Kendall Square, Cambridge, MA 02139 * (617) 225-2500 |
| The company's phage display technology has broad potential commercial applications in the fields of therapeutic, diagnostic and separations products. |
| Manager | Tier | Phone |
| Salomon Smith Barney | Lead Manager | (212) 723-7300 |
| CIBC Oppenheimer & Company | Co-manager | (212) 667-7400 |
| Pacific Crest Securities Inc. | Co-manager | (503) 790-0293 |
| NASNTL: | DYAX | Service: | SIC 8731 | |
| Type of Shares: | Common Shares | Filing Date: | 3/23/98 | |
| U.S. Shares Filed: | 2,300,000 | Filing Range: | $6.00 - $7.00 | |
| Non-U.S. Shares Filed: | 0 | Offering Amount: | $14,950,000 | |
| Primary Shares: | 2,300,000 | Expenses: | $900,000 | |
| Secondary Shares: | 0 | Post-IPO Shares: | 9,761,353 | |
| Employees: | 84 |
| Issuer's Law Firm: | Palmer & Dodge |
| Bank's Law Firm: | Hale and Dorr |
| Registrar/Transfer Agent: | Boston Equiserve Limited Partnership |
| Auditor: | Coopers & Lybrand |
Dollar amounts in U.S. millions except for per share data | |||||
| Full Year Audited Income | Latest Unaudited Income | Prior Audited Income | Balance Sheet | ||
| 12/31/97 | 12/31/97 | ||||
| Revenue: | $9.78 | Assets: | $10.53 | ||
| Net Income: | -$5.54 | Curr Assets: | $9.10 | ||
| EPS: | -$0.83 | Liabilities: | $4.27 | ||
| Prior EPS: | Curr Liab: | $3.19 | |||
| Cash Flow/Oper: | -$5.72 | Equity: | $6.26 | ||
| Cash Flow/Fin: | $2.90 | Cash: | $4.66 | ||
| Cash Flow/Inv: | -$0.96 | Working Cap: | $5.91 | ||
| Use of Proceeds |
| Proceeds from the proposed offering will be used to fund research and development, repayment of indebtedness, working capital and other general corporate purposes, including possible technology in-licensing and acquisitions. |